These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 30829681)

  • 1. Orthotopic Liver Transplant in a Patient Anticoagulated With Rivaroxaban: A Case Report.
    Vuilleumier PH; Nagler M; Beldi G; Vogt A
    A A Pract; 2019 Jul; 13(2):54-57. PubMed ID: 30829681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
    JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bilateral adrenal gland hemorrhage in a patient treated with rivaroxaban.
    Comuth W; Christiansen JJ; Bloch-Münster AM; Husted S
    Blood Coagul Fibrinolysis; 2017 Jan; 28(1):102-104. PubMed ID: 26919451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban for the treatment of superficial vein thrombosis, experience at King's College Hospital.
    Clapham RE; Speed V; Czuprynska J; Gazes A; Guppy S; Patel RK; Rea C; Vadher B; Arya R; Roberts LN
    Br J Haematol; 2022 Jan; 196(1):e3-e6. PubMed ID: 34355385
    [No Abstract]   [Full Text] [Related]  

  • 5. Superior mesenteric artery thrombosis after abrupt discontinuation of rivaroxaban.
    Adams CB; Acquisto NM; Rotoli JM; LoStracco T; Shamaskin AR; Pasternack JS
    Am J Emerg Med; 2016 Apr; 34(4):764.e5-7. PubMed ID: 26439093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) study.
    Okumura Y; Fukuda I; Nakamura M; Yamada N; Takayama M; Maeda H; Yamashita T; Ikeda T; Mo M; Yamazaki T; Hirayama A;
    BMJ Open; 2018 Jun; 8(6):e020286. PubMed ID: 29934383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracardiac Thrombus Following Rivaroxaban Treatment in a Patient with Atrial Fibrillation Associated with Rheumatic Heart Disease.
    Ohara H; Yamamoto S; Nagano K; Hashikawa K
    J Stroke Cerebrovasc Dis; 2019 Nov; 28(11):104325. PubMed ID: 31427189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of Oral Xa Inhibitor for Management of Ischemic Stroke Associated with Thrombosis in the Pulmonary Vein Stump after Lung Resection.
    Amemiya T; Shono T; Yamagami K; Takagishi S; Toma H; Kobarai T; Eguchi T; Hirota I
    J Stroke Cerebrovasc Dis; 2019 Nov; 28(11):104321. PubMed ID: 31422005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient adherence to rivaroxaban in deep vein thrombosis, a cohort study in Switzerland: quantitative results.
    Dotta-Celio J; Alatri A; Locatelli I; Salvi M; Bugnon O; Schneider MP; Mazzolai L
    Int J Clin Pharm; 2019 Dec; 41(6):1625-1633. PubMed ID: 31776778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Greenlight™ photovaporization of the prostate in patients under rivaroxaban: Lesson learned after the first cases.
    Charbonneau H; Pathak A; Albenque JP; Misrai V
    Prog Urol; 2016 Apr; 26(5):273-5. PubMed ID: 26970929
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and Efficacy of Novel Oral Anticoagulants vs Low Molecular Weight Heparin for Thromboprophylaxis in Large-Volume Liposuction and Body Contouring Procedures.
    Morales R; Ruff E; Patronella C; Mentz H; Newall G; Hustak KL; Fortes P; Bush A
    Aesthet Surg J; 2016 Apr; 36(4):440-9. PubMed ID: 26961988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease.
    Coleman CI; Baker WL; Meinecke AK; Eriksson D; Martinez BK; Bunz TJ; Alberts MJ
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):159-166. PubMed ID: 31549153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosing of rivaroxaban by indication: getting the right dose for the patient.
    Escolar G; Carne X; Arellano-Rodrigo E
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1665-77. PubMed ID: 26329812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention.
    Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
    Circ Cardiovasc Interv; 2019 Feb; 12(2):e007124. PubMed ID: 30704287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban Use in Patients with Hemoglobinopathies.
    Apostolou C; Klonizakis P; Mainou M; Kapsali E; Kafantari K; Kotsiafti A; Vetsiou E; Vakalopoulou S; Vlachaki E
    Hemoglobin; 2017 May; 41(3):223-224. PubMed ID: 28950780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary Venous Thromboembolism in an Acutely Ill Medical Patient Receiving Rivaroxaban.
    Saleem A
    J Coll Physicians Surg Pak; 2017 Sep; 27(9):S129-S130. PubMed ID: 28969751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultrasound Aspects and Recanalization Rates in Patients with Lower-Limb Deep Venous Thrombosis Treated with Rivaroxaban.
    de Athayde Soares R; Matielo MF; Brochado Neto FC; Almeida RD; Sacilotto R
    Ann Vasc Surg; 2020 Aug; 67():293-299. PubMed ID: 31931131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivaroxaban (Xarelto) - a new peripheral artery disease indication.
    Med Lett Drugs Ther; 2021 Nov; 63(1636):172-173. PubMed ID: 35085206
    [No Abstract]   [Full Text] [Related]  

  • 19. Rivaroxaban (Xarelto) plus aspirin for secondary prevention of cardiovascular events.
    Med Lett Drugs Ther; 2018 Dec; 60(1561):196-197. PubMed ID: 30653475
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital.
    Tellor KB; Patel S; Armbruster AL; Daly MW
    J Clin Pharm Ther; 2015 Aug; 40(4):447-51. PubMed ID: 26010016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.